Boothbay Fund Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Boothbay Fund Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-24,121	Closed	-$2.59M	–	2551
2023 Q1	$2.59M	Sell	24,121 -30,976	-56%	-$3.57M	0.05%	546
2022 Q4	$6.06M	Buy	55,097 +16,347	+42%	+$1.06M	0.14%	164
2022 Q3	$2.29M	Buy	+38,750	New	+$1.77M	0.06%	509

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Boothbay Fund Management's RXDX Position: Q2 2023 in Review

Boothbay Fund Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 24,121 shares — an estimated $2.59M sold.

Boothbay Fund Management first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $6.06M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Boothbay Fund Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 24,121 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.59M.
Boothbay Fund Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Boothbay Fund Management's Prometheus Biosciences, Inc. Common Stock position peaked at $6.06M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.